Skip to main content
. 2024 Jan 19;10:183–190. doi: 10.1016/j.ijregi.2024.01.006

Table 3.

Comparison of demographic and medical variables with lung computed tomography abnormalities.

Lung computed tomography abnormalities
Ground glass
Nodular
Consolidation
Opacity
n,% P-value
OR
(95% CI)
n,% P-value
OR
(95% CI)
n,% P-value
OR
(95% CI)
n,% P-value
OR
(95% CI)
Age
(n, %)
< 60
(n = 79)
59 (74.7) > 0.05
1.21
(0.98-1.50)
08 (10.1) > 0.05
0.99
(0.86-1.02)
37
(46.8)
> 0.05
1.08
(0.80-1.46)
24 (30.4) > 0.05
1.20
(0.95-1.52)
≥ 60
(n = 81)
50 (51.7) 03 (3.7) 41 (50.6) 34
(42.0)
Variants
(n, %)
Alpha
(n=26)
24
(92.3)
< 0.05 08
(30.8)
< 0.001 04
(15.4)
< 0.001 01
(3.8)
< 0.001
Delta
(n=98)
66
(67.3)
0
(0.0)
63
(64.3)
42
(42.9)
Omicron
(n = 36)
19
(52.8)
03
(8.3)
11
(30.6)
15
(41.7)
Vaccine None
(n=105)
72 (68.6) > 0.05 09 (8.6) > 0.05 52 (49.5) > 0.05 34 (32.4) > 0.05
1 dose
(n = 17)
12 (70.6) 00 (0.0) 11 (64.7) 06 (35.3)
≥2 doses
(n = 38)
25 (65.8) 02 (5.3) 15 (39.5) 18 (47.4)
Oxygen therapies Not used
(n = 68)
52 (76.5) > 0.05 08 (11.8) > 0.05 18 (26.5) < 0.001 18 (26.5) < 0.05
Mask cannula
(n = 68)
40 (58.8) 02 (2.9) 47 (69.1) 32 (47.1)
Ventilator
(n = 24)
17 (70.8) 01 (4.2) 13 (54.2) 08 (33.3)
Severities Non severe
(n = 72)
54 (75.0) > 0.05
0.83
(0.68-1.03)
08
(11.1)
> 0.05
1.09
(0.99-1.19)
17 (23.8) < 0.001
2.94
(1.89-4.56)
21
(29.2)
> 0.05
0.82
(0.65-1.03)
Severe
(n = 88)
55
(62.5)
03
(3.4)
61
(69.3)
37
(42.0)
Treatment outcomes Survive
(n = 140)
95 (67.9) > 0.05
1.07
(0.53-2.18)
10 (7.1) > 0.05
0.98
(0.88-1.09)
66 (47.1) > 0.05
1.32
(0.76-2.31)
49 (35.0) > 0.05
1.18
(0.78-1.79)
Death
(n = 20)
14 (70.0) 01 (5.0) 12 (60.0) 09 (45.0)

CI, confidence interval; OR, odds ratio.